The stock closed at HK$33.28, more than double its HK$12.90 IPO price, which was set at the low end of the marketed range.
The share sale’s success builds on the rally of health-care stocks, which have been the best performers on the Hang Seng Composite Index this year. Ab&B, which sells an influenza vaccine, was so sought after among retail investors that they applied for more than $20 billion worth of margin loans to bid for the ...